MA28946B1 - Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase - Google Patents
Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinaseInfo
- Publication number
- MA28946B1 MA28946B1 MA29848A MA29848A MA28946B1 MA 28946 B1 MA28946 B1 MA 28946B1 MA 29848 A MA29848 A MA 29848A MA 29848 A MA29848 A MA 29848A MA 28946 B1 MA28946 B1 MA 28946B1
- Authority
- MA
- Morocco
- Prior art keywords
- methylpiperazin
- ylamino
- benzamide
- pyrimidin
- ylmethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61974404P | 2004-10-18 | 2004-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28946B1 true MA28946B1 (fr) | 2007-10-01 |
Family
ID=36202610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29848A MA28946B1 (fr) | 2004-10-18 | 2007-04-25 | Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080255139A1 (fr) |
EP (1) | EP1804800B1 (fr) |
JP (1) | JP2008516898A (fr) |
KR (1) | KR20070083705A (fr) |
CN (1) | CN101035535A (fr) |
AT (1) | ATE492277T1 (fr) |
AU (1) | AU2005297321A1 (fr) |
BR (1) | BRPI0517083A (fr) |
CA (1) | CA2580976A1 (fr) |
DE (1) | DE602005025514D1 (fr) |
IL (1) | IL182419A0 (fr) |
MA (1) | MA28946B1 (fr) |
MX (1) | MX2007004660A (fr) |
NO (1) | NO20072501L (fr) |
NZ (1) | NZ554009A (fr) |
RU (1) | RU2007118420A (fr) |
TN (1) | TNSN07141A1 (fr) |
WO (1) | WO2006042362A1 (fr) |
ZA (1) | ZA200702316B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011502266A (ja) * | 2007-10-31 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Fms治療に対する応答を評価するバイオマーカー |
EP3246046A4 (fr) * | 2015-01-13 | 2018-12-05 | Kyoto University | Agent pour la prévention et/ou le traitement de la sclérose latérale amyotrophique |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
CA2446939C (fr) * | 2001-05-16 | 2005-08-02 | Matthias Stein-Gerlach | Derives de pyridylpyrimidine utilises comme composes actifs contre des infections et des maladies a prions |
AU2003295320A1 (en) * | 2002-06-26 | 2004-04-08 | The Ohio State University Research Foundation | The method for reducing inflammation using sti-571 or its salt |
-
2005
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/fr active Application Filing
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de active Active
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Application Discontinuation
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
- 2005-10-17 CA CA002580976A patent/CA2580976A1/fr not_active Abandoned
- 2005-10-17 EP EP05793868A patent/EP1804800B1/fr active Active
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070083705A (ko) | 2007-08-24 |
AU2005297321A1 (en) | 2006-04-27 |
MX2007004660A (es) | 2007-10-17 |
NO20072501L (no) | 2007-05-15 |
ATE492277T1 (de) | 2011-01-15 |
US20080255139A1 (en) | 2008-10-16 |
TNSN07141A1 (en) | 2008-11-21 |
JP2008516898A (ja) | 2008-05-22 |
EP1804800A4 (fr) | 2008-03-19 |
CN101035535A (zh) | 2007-09-12 |
DE602005025514D1 (de) | 2011-02-03 |
CA2580976A1 (fr) | 2006-04-27 |
EP1804800A1 (fr) | 2007-07-11 |
WO2006042362A1 (fr) | 2006-04-27 |
NZ554009A (en) | 2010-09-30 |
EP1804800B1 (fr) | 2010-12-22 |
ZA200702316B (en) | 2008-09-25 |
RU2007118420A (ru) | 2008-11-27 |
BRPI0517083A (pt) | 2008-09-30 |
IL182419A0 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49952B1 (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
AR112118A2 (es) | Inhibidores de pi-3 quinasa | |
PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
TWI347186B (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
RS54608B1 (en) | CGRP RECEPTOR ANTAGONITY | |
PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
MA31517B1 (fr) | Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
RU2016149804A (ru) | Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой | |
WO2008059551A3 (fr) | Procédé de préparation d'imatinib et d'intermédiaires correspondants | |
NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
HK1072192A1 (en) | Treatment of rheumatoid arthritis using imatinib | |
JP2008542390A5 (fr) | ||
MA28946B1 (fr) | Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase | |
NZ593058A (en) | (r)-3-(e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors | |
MA35636B1 (fr) | Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide | |
NO20056188L (no) | Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes | |
RU2020127993A (ru) | Терапевтическое средство для лечения гепатоцеллюлярной карциномы | |
CL2008002461A1 (es) | Compuesto 4-((trans)-2-(4-ciclobutilpiperazina-1-carbonil)ciclopropil)benzamida o un enantiómero, o una sal farmacéuticamente aceptable o una mezcla del mismo |